- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04964934
Phase-III-Studie zur Bewertung von AZD9833+ CDK4/6-Inhibitor bei HR+/HER2-MBC mit nachweisbarer ESR1m vor Progression (SERENA-6) (SERENA-6)
Eine doppelblinde, randomisierte Phase-III-Studie zur Bewertung der Umstellung auf AZD9833 (eine orale SERD der nächsten Generation) + CDK4/6-Inhibitor (Palbociclib oder Abemaciclib) im Vergleich zur Fortführung des Aromatase-Inhibitors (Letrozol oder Anastrozol) + CDK4/6-Inhibitor bei HR+/ HER2-MBC-Patienten mit nachweisbarer ESR1-Mutation ohne Krankheitsprogression während einer 1-Liter-Behandlung mit Aromatasehemmer + CDK4/6-Hemmer – eine ctDNA-geführte Early-Switch-Studie
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Arzneimittel: AZD9833
- Arzneimittel: Anastrozole placebo
- Arzneimittel: Letrozole placebo
- Arzneimittel: Palbociclib
- Arzneimittel: Abemaciclib
- Arzneimittel: Luteinizing hormone-releasing hormone (LHRH) agonist
- Arzneimittel: Ribociclib
- Arzneimittel: AZD9833 Placebo
- Arzneimittel: Anastrozole
- Arzneimittel: Letrozole
Detaillierte Beschreibung
Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.
This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.
The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.
Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:
- palbociclib + anastrozole
- palbociclib + letrozole
- abemaciclib + anastrozole
- abemaciclib + letrozole
- ribociclib + anastrozole
- ribociclib + letrozole
During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.
In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.
The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.
The researchers also want to know more about how safe AZD9833 is.
The trial participants will be split into 2 groups:
- Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
- Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo
A placebo looks like a treatment but does not have any medicine in it.
A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.
The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.
Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.
Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Birtinya, Australien, 4575
- Research Site
-
Darlinghurst, Australien, 2010
- Research Site
-
-
-
-
-
Leuven, Belgien, 3000
- Research Site
-
Liège, Belgien, 4000
- Research Site
-
Namur, Belgien, 5000
- Research Site
-
-
-
-
-
Haskovo, Bulgarien, 6300
- Research Site
-
Panagyurishte, Bulgarien, 4500
- Research Site
-
Pleven, Bulgarien, 5804
- Research Site
-
Plovdiv, Bulgarien, 4004
- Research Site
-
Sofia, Bulgarien, 1431
- Research Site
-
Sofia, Bulgarien, 1407
- Research Site
-
Sofia, Bulgarien, 1527
- Research Site
-
Sofia, Bulgarien, 1330
- Research Site
-
Sofia, Bulgarien, 1303
- Research Site
-
-
-
-
-
Ansbach, Deutschland, 91522
- Research Site
-
Augsburg, Deutschland, 86156
- Research Site
-
Bonn, Deutschland, 53111
- Research Site
-
Chemnitz, Deutschland, 09116
- Research Site
-
Dresden, Deutschland, 01307
- Research Site
-
Erlangen, Deutschland, 91054
- Research Site
-
Essen, Deutschland, 45130
- Research Site
-
Freiburg im Breisgau, Deutschland, 79110
- Research Site
-
Hösbach, Deutschland, 63768
- Research Site
-
Immenstadt im Allgäu, Deutschland, 87509
- Research Site
-
Koblenz, Deutschland, 56068
- Research Site
-
Leipzig, Deutschland, 4103
- Research Site
-
Mannheim, Deutschland, 68167
- Research Site
-
München, Deutschland, 80634
- Research Site
-
Paderborn, Deutschland, 33098
- Research Site
-
Ratingen, Deutschland, 40878
- Research Site
-
Ravensburg, Deutschland, 88212
- Research Site
-
Regensburg, Deutschland, 93053
- Research Site
-
Stade, Deutschland, 21680
- Research Site
-
Tübingen, Deutschland, 72076
- Research Site
-
Ulm, Deutschland, 89075
- Research Site
-
-
-
-
-
Avignon, Frankreich, 84918
- Research Site
-
Brest, Frankreich, 29200
- Research Site
-
Clermont-Ferrand, Frankreich, 63050
- Research Site
-
Dijon, Frankreich, 21079
- Research Site
-
Limoges, Frankreich, 83000
- Research Site
-
Lorient, Frankreich, 56322
- Research Site
-
Lyon, Frankreich, 69373
- Research Site
-
Marseille, Frankreich, 13273
- Research Site
-
Metz-Tessy, Frankreich, 74370
- Research Site
-
Nîmes, Frankreich, 30029
- Research Site
-
Paris, Frankreich, 75248
- Research Site
-
Rouen, Frankreich, 76021
- Research Site
-
Saint-Cloud, Frankreich, 92210
- Research Site
-
Saint-Herblain, Frankreich, 44805
- Research Site
-
Toulouse, Frankreich, 31100
- Research Site
-
Tours, Frankreich, 37000
- Research Site
-
Vandœuvre-lès-Nancy, Frankreich, 54519
- Research Site
-
Vantoux, Frankreich, 57070
- Research Site
-
Villejuif, Frankreich, 94805
- Research Site
-
-
-
-
-
Beersheba, Israel, 8410101
- Research Site
-
Haifa, Israel, 3109601
- Research Site
-
Jerusalem, Israel, 91120
- Research Site
-
Petah Tikva, Israel, 494142
- Research Site
-
Ramat Gan, Israel, 5262000
- Research Site
-
-
-
-
-
Bergamo, Italien, 24127
- Research Site
-
Bologna, Italien, 40138
- Research Site
-
Florence, Italien, 50134
- Research Site
-
Meldola, Italien, 47014
- Research Site
-
Milan, Italien, 20141
- Research Site
-
Milan, Italien, 20132
- Research Site
-
Misterbianco, Italien, 95045
- Research Site
-
Naples, Italien, 80131
- Research Site
-
Padova, Italien, 35128
- Research Site
-
Roma, Italien, 00168
- Research Site
-
Rozzano, Italien, 20089
- Research Site
-
-
-
-
-
Chiba, Japan, 260-8717
- Research Site
-
Chūōku, Japan, 104-0045
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Research Site
-
Hirakata-shi, Japan, 573-1191
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Research Site
-
Kumamoto, Japan, 860-8556
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Matsuyama, Japan, 791-0280
- Research Site
-
Nagoya, Japan, 464-8681
- Research Site
-
Nagoya, Japan, 467-8602
- Research Site
-
Niigata, Japan, 951-8566
- Research Site
-
Osaka, Japan, 540-0006
- Research Site
-
Osaka, Japan, 541-8567
- Research Site
-
Ota-shi, Japan, 373-8550
- Research Site
-
Sapporo, Japan, 003-0804
- Research Site
-
Shinagawa-ku, Japan, 142-8666
- Research Site
-
Shinjuku-ku, Japan, 162-8655
- Research Site
-
Takasaki-shi, Japan, 370-0829
- Research Site
-
Takatsuki-shi, Japan, 569-8686
- Research Site
-
Tsukuba, Japan, 305-8577
- Research Site
-
Yokohama, Japan, 241-8515
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- Research Site
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- Research Site
-
-
Quebec
-
Lévis, Quebec, Kanada, G6V 3Z1
- Research Site
-
Montreal, Quebec, Kanada, H2X 0C1
- Research Site
-
Montreal, Quebec, Kanada, H3T 1E2
- Research Site
-
Montreal, Quebec, Kanada, H1T 2M4
- Research Site
-
Québec, Quebec, Kanada, G1S 4L8
- Research Site
-
-
-
-
-
Drammen, Norwegen, 3004
- Research Site
-
Oslo, Norwegen, 0450
- Research Site
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Research Site
-
Gdynia, Polen, 81-519
- Research Site
-
Koszalin, Polen, 75-581
- Research Site
-
Lodz, Polen, 90-302
- Research Site
-
Poznan, Polen, 60-693
- Research Site
-
Rzeszów, Polen, 35-001
- Research Site
-
Tomaszów Mazowiecki, Polen, 97-200
- Research Site
-
Warsaw, Polen, 02-781
- Research Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- Research Site
-
Lisbon, Portugal, 1649-035
- Research Site
-
Lisbon, Portugal, 1400-038
- Research Site
-
Lisbon, Portugal, 1500-650
- Research Site
-
Lisbon, Portugal, 1449-005
- Research Site
-
Loures, Portugal, 2674-514
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
Porto, Portugal, 4200-319
- Research Site
-
Porto, Portugal, 4200-072
- Research Site
-
Vila Nova de Gaia, Portugal, 4434-502
- Research Site
-
-
-
-
-
Moscow, Russland, 111123
- Research Site
-
Moscow, Russland, 143423
- Research Site
-
Moscow, Russland, 129090
- Research Site
-
Nizhny Novgorod, Russland, 603126
- Research Site
-
Podolsk, Russland, 142100
- Research Site
-
Saint Petersburg, Russland, 197758
- Research Site
-
Saint Petersburg, Russland, 194017
- Research Site
-
-
-
-
-
Bern, Schweiz, CH-3010
- Research Site
-
Chur, Schweiz, CH-7000
- Research Site
-
Winterthur, Schweiz, 8401
- Research Site
-
-
-
-
-
Banská Bystrica, Slowakei, 974 01
- Research Site
-
Bratislava, Slowakei, 833 01
- Research Site
-
Košice, Slowakei, 041 91
- Research Site
-
Michalovce, Slowakei, 07101
- Research Site
-
Partizánske, Slowakei, 958 01
- Research Site
-
-
-
-
-
A Coruña, Spanien, 15009
- Research Site
-
Badalona, Spanien, 08003
- Research Site
-
Barcelona, Spanien, 8035
- Research Site
-
L'Hospitalet de Llobregat, Spanien, 08908
- Research Site
-
Madrid, Spanien, 28041
- Research Site
-
Madrid, Spanien, 28040
- Research Site
-
Murcia, Spanien, 30008
- Research Site
-
Málaga, Spanien, 29010
- Research Site
-
Sant Joan Despí, Spanien, 08970
- Research Site
-
Seville, Spanien, 41013
- Research Site
-
Valencia, Spanien, 46010
- Research Site
-
-
-
-
-
Cheonan-si, Südkorea, 31151
- Research Site
-
Daegu, Südkorea, 42415
- Research Site
-
Goyang-si, Südkorea, 10408
- Research Site
-
Seongnam-si, Südkorea, 13620
- Research Site
-
Seongnam-si, Südkorea, 463-712
- Research Site
-
Seoul, Südkorea, 02841
- Research Site
-
Seoul, Südkorea, 03080
- Research Site
-
Seoul, Südkorea, 03722
- Research Site
-
Seoul, Südkorea, 05505
- Research Site
-
Seoul, Südkorea, 06273
- Research Site
-
Seoul, Südkorea, 06351
- Research Site
-
Seoul, Südkorea, 06591
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Research Site
-
Taichung, Taiwan, 40705
- Research Site
-
Tainan, Taiwan, 70403
- Research Site
-
Tainan, Taiwan, 710
- Research Site
-
Taipei, Taiwan, 100
- Research Site
-
Taipei, Taiwan
- Research Site
-
Taipei, Taiwan, 11490
- Research Site
-
Taipei, Taiwan, 23561
- Research Site
-
Taipei, Taiwan, 11259
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Adana, Türkei (türkiye), 01120
- Research Site
-
Ankara, Türkei (türkiye), 06100
- Research Site
-
Ankara, Türkei (türkiye), 06520
- Research Site
-
Ankara, Türkei (türkiye), 06010
- Research Site
-
Ankara, Türkei (türkiye), 06340
- Research Site
-
Cordaleo, Türkei (türkiye), 35575
- Research Site
-
Izmir, Türkei (türkiye), 35100
- Research Site
-
Izmir, Türkei (türkiye), 35360
- Research Site
-
Kadıkoy/Istanbul, Türkei (türkiye), 34722
- Research Site
-
Kayseri, Türkei (türkiye), 38039
- Research Site
-
-
-
-
-
Budapest, Ungarn, 1122
- Research Site
-
Budapest, Ungarn, 1062
- Research Site
-
Miskolc, Ungarn, 3526
- Research Site
-
Szekszárd, Ungarn, 7100
- Research Site
-
Szolnok, Ungarn, 5000
- Research Site
-
Zalaegerszeg, Ungarn, 8900
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Research Site
-
-
Arkansas
-
Hot Springs, Arkansas, Vereinigte Staaten, 71913
- Research Site
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- Research Site
-
-
California
-
Long Beach, California, Vereinigte Staaten, 90806
- Research Site
-
San Diego, California, Vereinigte Staaten, 92123
- Research Site
-
Santa Rosa, California, Vereinigte Staaten, 92805
- Research Site
-
-
Colorado
-
Grand Junction, Colorado, Vereinigte Staaten, 81501
- Research Site
-
Lone Tree, Colorado, Vereinigte Staaten, 80124
- Research Site
-
-
Florida
-
Fort Myers, Florida, Vereinigte Staaten, 33901
- Research Site
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Research Site
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Research Site
-
St. Petersburg, Florida, Vereinigte Staaten, 33705
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30318
- Research Site
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Research Site
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Research Site
-
-
Illinois
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Vereinigte Staaten, 46804
- Research Site
-
Indianapolis, Indiana, Vereinigte Staaten, 46250
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21202
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Research Site
-
Fairhaven, Massachusetts, Vereinigte Staaten, 02719
- Research Site
-
Foxborough, Massachusetts, Vereinigte Staaten, 02035
- Research Site
-
Milford, Massachusetts, Vereinigte Staaten, 01757
- Research Site
-
South Weymouth, Massachusetts, Vereinigte Staaten, 02190
- Research Site
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Research Site
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Research Site
-
-
Mississippi
-
Oxford, Mississippi, Vereinigte Staaten, 38655
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64111
- Research Site
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Research Site
-
-
Montana
-
Billings, Montana, Vereinigte Staaten, 59101
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68130
- Research Site
-
-
New Jersey
-
Camden, New Jersey, Vereinigte Staaten, 08103
- Research Site
-
Ridgewood, New Jersey, Vereinigte Staaten, 07450
- Research Site
-
-
New York
-
Brooklyn, New York, Vereinigte Staaten, 11215
- Research Site
-
East Syracuse, New York, Vereinigte Staaten, 13057
- Research Site
-
New Hyde Park, New York, Vereinigte Staaten, 11042
- Research Site
-
New York, New York, Vereinigte Staaten, 10065
- Research Site
-
New York, New York, Vereinigte Staaten, 11355
- Research Site
-
Shirley, New York, Vereinigte Staaten, 11967
- Research Site
-
-
North Carolina
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Research Site
-
-
Ohio
-
Canton, Ohio, Vereinigte Staaten, 44710
- Research Site
-
Cincinnati, Ohio, Vereinigte Staaten, 45220
- Research Site
-
Columbus, Ohio, Vereinigte Staaten, 43219
- Research Site
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97213
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Research Site
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- Research Site
-
York, Pennsylvania, Vereinigte Staaten, 17403
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Research Site
-
West Columbia, South Carolina, Vereinigte Staaten, 29169
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- Research Site
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Research Site
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Research Site
-
-
Texas
-
Bedford, Texas, Vereinigte Staaten, 76022
- Research Site
-
Dallas, Texas, Vereinigte Staaten, 75246
- Research Site
-
Houston, Texas, Vereinigte Staaten, 77030
- Research Site
-
Houston, Texas, Vereinigte Staaten, 77024
- Research Site
-
Longview, Texas, Vereinigte Staaten, 75601
- Research Site
-
San Antonio, Texas, Vereinigte Staaten, 78240
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84106
- Research Site
-
-
Virginia
-
Midlothian, Virginia, Vereinigte Staaten, 23114
- Research Site
-
Norfolk, Virginia, Vereinigte Staaten, 23502
- Research Site
-
-
Washington
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Research Site
-
-
Wisconsin
-
Waukesha, Wisconsin, Vereinigte Staaten, 53226
- Research Site
-
-
-
-
-
Blackpool, Vereinigtes Königreich, FY3 8NR
- Research Site
-
Cambridge, Vereinigtes Königreich, CB2 0QQ
- Research Site
-
London, Vereinigtes Königreich, SW3 6JJ
- Research Site
-
London, Vereinigtes Königreich, WC1N 3BG
- Research Site
-
Manchester, Vereinigtes Königreich, M20 4BX
- Research Site
-
Newport, Vereinigtes Königreich, NP10 8FZ
- Research Site
-
Nottingham, Vereinigtes Königreich, NG5 1PB
- Research Site
-
Portsmouth, Vereinigtes Königreich, PO6 3LY
- Research Site
-
Reading, Vereinigtes Königreich, RG2 9LH
- Research Site
-
Sheffield, Vereinigtes Königreich, S10 2SJ
- Research Site
-
Sutton, Vereinigtes Königreich, SM2 5PT
- Research Site
-
Taunton, Vereinigtes Königreich, TA1 5DA
- Research Site
-
-
-
-
-
Graz, Österreich, 8036
- Research Site
-
Innsbruck, Österreich, 6020
- Research Site
-
Salzburg, Österreich, 5020
- Research Site
-
Vienna, Österreich, 1130
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
INCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:
- Have advanced breast cancer that is not able to be treated with surgery or radiation;
- Have an ESR1 mutation in their cancer;
- Have breast cancer that is HR-positive and HER2-negative;
- Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
- Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
- Are able to do their daily activities;
- Are at least 18.
Full list of inclusion criteria:
- Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
- Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
- Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
- Eastern Cooperative Oncology Group performance status of 0 or 1;
- ESR1m detected by central testing of ctDNA with Guardant360® CDx;
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
- Adequate organ and marrow function.
EXCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:
- Had certain types of tumors in the past that may come back;
- Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
- Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.
Full list of exclusion criteria:
- Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
- Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
- Patient with known or family history of severe heart disease;
- Previous treatment with AZD9833, investigational SERDs or fulvestrant;
- Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
- Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: AZD9833 + palbociclib, abemaciclib or ribociclib
The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily) |
Dosage formulation: AZD9833 tablets will be administered orally Dosage formulation: anastrozole placebo tablets will be administrated orally. Dosage formulation: letrozole placebo tablets will be administered orally. Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally |
|
Aktiver Komparator: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib
The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily) |
Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally Dosage formulation: AZD9833 placebo tablets will be administrated orally. Dosage formulation: anastrozole tablets will be administered orally. Dosage formulation: letrozole tablets will be administered orally. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Zeitfenster: From randomization until the earlier of the progression event or death (approximately 2 years)
|
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death. |
From randomization until the earlier of the progression event or death (approximately 2 years)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival 2 (PFS2)
Zeitfenster: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death. |
From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
|
Overall survival (OS)
Zeitfenster: From randomization until the date of death due to any cause (approximately 5 years)
|
The OS is defined as the time from randomization to death due to any cause. |
From randomization until the date of death due to any cause (approximately 5 years)
|
|
Chemotherapy free survival
Zeitfenster: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause. |
From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
|
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
Zeitfenster: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1. |
From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
|
Clinical benefit rate at 24 weeks (CBR24)
Zeitfenster: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment) |
At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
|
Change from baseline in EORTC QLQ-C30 scale scores
Zeitfenster: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Change from baseline in EORTC QLQ-BR23 scale scores
Zeitfenster: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Plasma concentration of AZD9833 at specified timepoints
Zeitfenster: on Day 15 for each patient
|
To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration. |
on Day 15 for each patient
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1.
- Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
- Brufsky A, Park YH, Bidard FC, Mayer EL, Janni W, Ma C, Cristofanilli M, Bianchini G, Iwata H, Fasching PA, Nowecki Z, Pascual J, Chen SC, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Jung KH, Kikawa Y, Baird RD, Habash R, Sugarman R, Fox S, Selvi Miralles M, Huang Bartlett C, Turner N. SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. Oncologist. 2026 Aug 6;31(9):oyag278. doi: 10.1093/oncolo/oyag278.
- Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky AM, Fasching PA, Nowecki Z, Pascual J, Karadurmus N, Gal-Yam E, Chung WP, Im SA, Zambelli A, Dalenc F, Oliveira M, Ishiguro H, Huang CS, Klinowska T, Fox S, Morrow C, Robert L, Huang-Bartlett C, Bidard FC. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026 Aug;27(8):941-958. doi: 10.1016/S1470-2045(26)00287-1. Epub 2026 Jul 13.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Neubildungen
- Doppelblind
- Phase III
- Metastatisch
- Ribociclib
- Antineoplastische Mittel
- Neoplasien der Brust
- Physiologische Wirkungen von Arzneimitteln
- Zufällig
- Endokrine Therapie
- Letrozol
- Palbociclib
- Neubildungen nach Standort
- Brusterkrankungen
- Abemaciclib
- Anastrozol
- Multizentrisch
- AZD9833
- Orales SERD der nächsten Generation
- Antagonisten
- Östrogenrezeptorantagonisten
- Hormonantagonisten
- Unterhemd
- ESR1m
- Behandlung wechseln
- Endokrine Resistenz
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neoplastische Prozesse
- Hautkrankheiten
- Pathologische Zustände, Anzeichen und Symptome
- Haut- und Bindegewebserkrankungen
- Neubildungen
- Neoplasien der Brust
- Neoplasma Metastasierung
- Brusterkrankungen
- Neubildungen nach Standort
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Hypophysenhormon-Freisetzungshormone
- Hypothalamische Hormone
- Peptidhormone
- Neuropeptide
- Peptide
- Aminosäuren, Peptide und Proteine
- Oligopeptide
- Nervengewebeproteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Azolen
- Nitrile
- Triazoles
- Letrozol
- Anastrozol
- Gonadotropin-freisetzendes Hormon
- Abemaciclib
- Ribociclib
- Palbociclib
- AZD9833
Andere Studien-ID-Nummern
- D8534C00001
- 2023-503990-39-00 (Andere Kennung: EU CT number)
- 2021-000546-17 (EudraCT-Nummer)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-Sharing-Zeitrahmen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-Sharing-Zugriffskriterien
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .